Global pharma major Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility, following a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Nilesh Gupta, Managing Director, Lupin said, "We are pleased to have received the EIR from the U.S. FDA for our Aurangabad facility. This underscores our commitment to upholding the highest standards of quality and compliance, and delivering trusted healthcare solutions to patients worldwide."